Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2019—Bio-Rad Laboratories announced the availability of Liquichek Serum Indices, used as part of laboratory interference testing to monitor an instrument’s ability to detect hemolysis, icterus, and lipemia specimen interferences in patient samples.
January 2019—Bio-Rad has announced its InteliQ selection of quality controls, available in barcoded, load-and-go tubes. This new configuration is designed to help optimize workflow efficiency and improve the laboratory’s risk management program.
October 2018—Bio-Rad announced the launch of recombinant beta-2 microglobulin from the company’s line of critical raw materials. This recombinant sourced tumor marker protein offers consistency and security over materials harvested from human sources.
October 2017—Bio-Rad Laboratories announced FDA clearance for its BioPlex 2200 ToRC IgM Assay, a fully automated assay for the detection of IgM class antibodies to Toxoplasma gondii, rubella, and cytomegalovirus offered in a multiplexed panel.
September 2017—Bio-Rad Laboratories has added four analytes to the company’s Liquichek Tumor Marker Control. The updated control received FDA 510(k) clearance and the CE mark and is available for the immunoassay-based tumor marker testing market.
March 2017—Illumina unveiled the NovaSeq series and announced the launch of the Illumina Bio-Rad Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference in January.
October 2016—Bio-Rad Laboratories launched Amplichek II quality control, which was issued a de novo clearance from the FDA. Amplichek II is the first in a series of infectious disease controls that the company is introducing to the molecular diagnostic testing market. It is an independent, multianalyte quality control that monitors the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of health care–associated infections.
July 2016—Bio-Rad Laboratories released its Liquichek Maternal Serum II Control, a frozen liquid human serum-based material designed to monitor the precision of laboratory test procedures used during maternal serum second trimester screening.
May 2016—Bio-Rad Laboratories announced CE IVD marking for its QX200 Droplet Digital PCR System. The technology, which partitions a DNA or RNA sample into 20,000 droplets and amplifies targeted sequences within each droplet, allows scientists to precisely detect and quantify low concentrations of target DNA and RNA sequences.
March 2016—Bio-Rad Laboratories and Illumina announced an exclusive partnership to develop a comprehensive next-generation sequencing workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells.
